Immune CAR Cell Preparation Technology Service-Tekbiotech-Yeast Display Service,Phage display technology

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Immune CAR Cell Preparation Technology Service

TekBiotech is a team of experts who are deeply engaged in antibody drug discovery. The average project experience is more than 10 years. It has established a complete antibody drug candidate molecule discovery platform based on the phage surface display technology platform, which can provide customers with a series of services related to the discovery of therapeutic biomacromolecules, including but not limited to VHH antibody, scFv antibody and Fab antibody discovery, CAR-T lead antibody sequence design, CAR-NK lead antibody sequence design and other services. After about 10 years of development, TekBiotech has successfully built an antibody discovery platform based on the antibody phage display technology platform, which can provide customers with high-quality antibody lead sequence discovery and downstream supporting development services more quickly.

█ Immunotherapeutic CAR Development Technology Services

CAR-T therapy refers to chimeric antigen receptor T-cell immunotherapy (similar to CAR-NK, but T cells are replaced with NK cells). This is a new type of precision targeted therapy for treating tumors. In recent years, it has achieved good results in clinical tumor treatment through optimization and improvement. It is a very promising new tumor immunotherapy method that can be accurate, fast, efficient, and may cure cancer.

T cells, also known as T lymphocytes, are a type of human white blood cells. They are derived from bone marrow hematopoietic stem cells, mature in the thymus, and then migrate to the human blood, lymph and surrounding tissues and organs to exert immune functions. Through genetic engineering technology, technicians transfer VHH antibody genes and scFv antibody genes into T cells through appropriate methods, such as lentiviral packaging. Through the membrane-localized expression of VHH or scFv, a special tumor-specific positioning navigation device CAR (tumor chimeric antigen receptor) is customized for T or NK cells, that is, CAR-T cells, which use their "positioning navigation device" CAR to specifically identify tumor cells in the body and release a large number of multiple effector factors through immune action, thereby efficiently killing tumor cells and achieving the purpose of treating malignant tumors.

Compared with traditional scFv antibodies (derived from ordinary IgG antibodies), VHH antibodies (also known as heavy chain antibodies) from camel-derived animals have a molecular weight of about 15kDa and are more stable. They are now widely used in the development of CAR-T lead antibodies. Through its own alpaca base, TekBiotech can provide customers with nano-antibody (VHH antibody) discovery services using healthy alpacas with pure background and clear sources.

█ CAR Cell Lead Antibody Drug Discovery Service

TekBiotech provides customers with CAR cell lead antibody discovery services, please see the table below for details:

Camel-derived Nanoantibody Development Service

scFv Antibody Development Service

█ CAR Cell Activity Identification Service

Immune CAR Cell Preparation Technology Service-tekbiotech1.png

Figure1 TekBiotech CAR-T/NK project service process

For CAR-T/NK, TekBiotech can provide value-added services:

-- CAR expression test

-- Target protein and lead antibody antigen recognition region specificity

-- Anti-idiotype test for lead antibody antigen recognition region

-- Fab antibody antigen recognition region detection for different target proteins

-- Cytokine release test

① Cytokine types: Y chain co-receptor family, IL-12 family, IL-1 superfamily, etc.

② Methods: enzyme-linked immunospot test (ELISpot), intracellular cytokine staining test (ICS), flow cytometry, etc.

-- In vitro cytotoxicity assay

Tekbiotech can provide in vitro cytotoxicity assays to validate and evaluate the cytotoxicity and possible adverse reactions of CAR-T cells. For example, some acute on-target/tumor toxicity (cytokine release syndrome, tumor lysis syndrome) or on-target/non-tumor toxicity that may be caused by CAR-T cell therapy, as well as the failure of CAR-T cell immortalization due to the increased cell-mediated toxicity that may occur due to antigen-independent proliferation of CAR-T cells.

--CAR cell proliferation assay

Tekbiotech's second- and third-generation CAR products can enhance the persistence of CAR-T cell or NK cell proliferation, and Tekbiotech can evaluate this activation and proliferation process through different assays, such as MTT, MTS, cell counting kit-8 (CCK-8), 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) combined with flow cytometry analysis and other technologies.

--Viability and biodistribution analysis

Tekbiotech can provide viability and biodistribution analysis to validate and evaluate the normal proliferation ability of CAR-T cells under physiological conditions, providing preclinical services for CAR-T cell therapy. For example, for CAR-T cell therapy, which is hindered by the limited replication lifespan of CAR-T cells and leads to reduced efficacy, activity and biodistribution analysis provide important support for the evaluation of the long-term therapeutic effect of CAR-T cells.

█ Advantages of Immunotherapeutic Cell (CAR-T/NK) Development Service Platform